Puzzle out Machine Learning Model-Explaining Disintegration Process in ODTs.
AutoML
ODTs
explainable models
machine learning
orally disintegrating tablets
partial dependence plots
shapley values
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
13 Apr 2022
13 Apr 2022
Historique:
received:
10
03
2022
revised:
10
04
2022
accepted:
11
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
24
4
2022
Statut:
epublish
Résumé
Tablets are the most common dosage form of pharmaceutical products. While tablets represent the majority of marketed pharmaceutical products, there remain a significant number of patients who find it difficult to swallow conventional tablets. Such difficulties lead to reduced patient compliance. Orally disintegrating tablets (ODT), sometimes called oral dispersible tablets, are the dosage form of choice for patients with swallowing difficulties. ODTs are defined as a solid dosage form for rapid disintegration prior to swallowing. The disintegration time, therefore, is one of the most important and optimizable critical quality attributes (CQAs) for ODTs. Current strategies to optimize ODT disintegration times are based on a conventional trial-and-error method whereby a small number of samples are used as proxies for the compliance of whole batches. We present an alternative machine learning approach to optimize the disintegration time based on a wide variety of machine learning (ML) models through the H2O AutoML platform. ML models are presented with inputs from a database originally presented by Han et al., which was enhanced and curated to include chemical descriptors representing active pharmaceutical ingredient (API) characteristics. A deep learning model with a 10-fold cross-validation NRMSE of 8.1% and an R
Identifiants
pubmed: 35456693
pii: pharmaceutics14040859
doi: 10.3390/pharmaceutics14040859
pmc: PMC9044744
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Jagiellonian University
ID : N42/DBS/000205
Organisme : qLIFE Priority Research Area under the program "Excellence Initiative-Research University" at Jagiellonian University
ID : NA
Références
Pharmacy (Basel). 2020 Oct 10;8(4):
pubmed: 33050437
Drug Dev Ind Pharm. 2018 Aug;44(8):1317-1327
pubmed: 29521132
Iran J Pharm Res. 2010 Fall;9(4):335-47
pubmed: 24381598
Drug Deliv Transl Res. 2017 Jun;7(3):450-459
pubmed: 28283842
NPJ Digit Med. 2020 Mar 26;3:47
pubmed: 32258429
Pharm Res. 2017 May;34(5):890-917
pubmed: 28251425
Int J Pharm. 2021 Nov 20;609:121146
pubmed: 34600058
Bosn J Basic Med Sci. 2007 Aug;7(3):279-83
pubmed: 17848158
Chem Pharm Bull (Tokyo). 2005 Dec;53(12):1536-9
pubmed: 16327184
Turk J Pharm Sci. 2017 Apr;14(1):40-48
pubmed: 32454593
Nat Rev Drug Discov. 2019 Jun;18(6):463-477
pubmed: 30976107
AAPS PharmSciTech. 2012 Dec;13(4):1120-9
pubmed: 22941425
Comput Struct Biotechnol J. 2019 Dec 26;18:241-252
pubmed: 33489002
Eur J Pharm Biopharm. 2007 Aug;67(1):268-76
pubmed: 17329086
AAPS J. 2014 Jul;16(4):771-83
pubmed: 24854893
Iran J Pharm Res. 2018 Fall;17(4):1150-1163
pubmed: 30568675
Acta Pol Pharm. 2016 Mar-Apr;73(2):453-60
pubmed: 27180438
Pharm Dev Technol. 2012 May-Jun;17(3):315-20
pubmed: 21142821
Pharm Dev Technol. 2001;6(1):39-51
pubmed: 11247274
Asian J Pharm Sci. 2018 Jul;13(4):336-342
pubmed: 32104407
J Drug Deliv Sci Technol. 2015 Jun 1;27:18-27
pubmed: 25914727
Drug Des Devel Ther. 2016 Oct 03;10:3211-3223
pubmed: 27757012
Int J Pharm. 2021 Apr 15;599:120439
pubmed: 33662471
AAPS PharmSciTech. 2012 Dec;13(4):1054-62
pubmed: 22899380
Eur J Pharm Biopharm. 2008 Aug;69(3):986-92
pubmed: 18396020
Saudi Pharm J. 2017 Nov;25(7):1086-1092
pubmed: 29158720
Arch Pharm Res. 2011 Nov;34(11):1945-56
pubmed: 22139694
Biomed Res Int. 2021 Dec 24;2021:6618934
pubmed: 34977245
Drug Des Devel Ther. 2015 Mar 05;9:1379-92
pubmed: 25834396
J Pharm Sci. 2020 Apr;109(4):1547-1557
pubmed: 31982393
Mater Sci Eng C Mater Biol Appl. 2016 Jan 1;58:826-34
pubmed: 26478377
Pharm Dev Technol. 2018 Jun;23(5):512-519
pubmed: 28657404
Int J Pharm. 2013 Oct 15;455(1-2):31-9
pubmed: 23933050
J Cheminform. 2018 Feb 06;10(1):4
pubmed: 29411163
J Comput Aided Mol Des. 2020 Oct;34(10):1013-1026
pubmed: 32361862
Eur J Pharm Biopharm. 2016 Sep;106:70-8
pubmed: 27016211
Saudi Pharm J. 2015 Sep;23(4):437-43
pubmed: 27134547
BMC Syst Biol. 2015 Oct 29;9:74
pubmed: 26515482
Drug Dev Ind Pharm. 2015 Jun;41(6):1006-16
pubmed: 24865111
Int J Pharm. 2013 May 1;448(1):1-8
pubmed: 23518366
AAPS PharmSciTech. 2020 Apr 15;21(3):115
pubmed: 32296987